BACKGROUND: Aortic arch plaques are a risk factor for ischemic stroke. Although the stroke mechanism is conceivably thromboembolic, no randomized studies have evaluated the efficacy of antithrombotic therapies in preventing recurrent events. METHODS AND RESULTS: The relationship between arch plaques and recurrent events was studied in 516 patients with ischemic stroke who were double-blindly randomized to treatment with warfarin or aspirin as part of the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), based on the Warfarin-Aspirin Recurrent Stroke Study (WARSS). Plaque thickness and morphology were evaluated by transesophageal echocardiography. End points were recurrent ischemic stroke or death over a 2-year follow-up. Large plaques (> or =4 mm) were present in 19.6% of patients; large complex plaques (those with ulcerations or mobile components) were seen in 8.5%. During follow-up, large plaques were associated with a significantly increased risk of events (adjusted hazard ratio [HR], 2.12; 95% confidence interval [CI], 1.04 to 4.32), especially those with complex morphology (HR, 2.55; 95 CI, 1.10 to 5.89). The risk was highest among cryptogenic stroke patients, both for large plaques (HR, 6.42; 95% CI, 1.62 to 25.46) and large complex plaques (HR, 9.50; 95% CI, 1.92 to 47.10). Event rates were similar in the warfarin and aspirin groups in the overall study population (16.4% versus 15.8%; P=0.43). CONCLUSIONS: In patients with stroke, especially cryptogenic stroke, large aortic plaques remain associated with an increased risk of recurrent stroke and death at 2 years despite treatment with warfarin or aspirin. Complex plaque morphology confers a slight additional increase in risk.
RCT Entities:
BACKGROUND: Aortic arch plaques are a risk factor for ischemic stroke. Although the stroke mechanism is conceivably thromboembolic, no randomized studies have evaluated the efficacy of antithrombotic therapies in preventing recurrent events. METHODS AND RESULTS: The relationship between arch plaques and recurrent events was studied in 516 patients with ischemic stroke who were double-blindly randomized to treatment with warfarin or aspirin as part of the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), based on the Warfarin-Aspirin Recurrent Stroke Study (WARSS). Plaque thickness and morphology were evaluated by transesophageal echocardiography. End points were recurrent ischemic stroke or death over a 2-year follow-up. Large plaques (> or =4 mm) were present in 19.6% of patients; large complex plaques (those with ulcerations or mobile components) were seen in 8.5%. During follow-up, large plaques were associated with a significantly increased risk of events (adjusted hazard ratio [HR], 2.12; 95% confidence interval [CI], 1.04 to 4.32), especially those with complex morphology (HR, 2.55; 95 CI, 1.10 to 5.89). The risk was highest among cryptogenic strokepatients, both for large plaques (HR, 6.42; 95% CI, 1.62 to 25.46) and large complex plaques (HR, 9.50; 95% CI, 1.92 to 47.10). Event rates were similar in the warfarin and aspirin groups in the overall study population (16.4% versus 15.8%; P=0.43). CONCLUSIONS: In patients with stroke, especially cryptogenic stroke, large aortic plaques remain associated with an increased risk of recurrent stroke and death at 2 years despite treatment with warfarin or aspirin. Complex plaque morphology confers a slight additional increase in risk.
Authors: Paul A Tunick; Ambika C Nayar; Gregory M Goodkin; Sunil Mirchandani; Steven Francescone; Barry P Rosenzweig; Robin S Freedberg; Edward S Katz; Robert M Applebaum; Itzhak Kronzon Journal: Am J Cardiol Date: 2002-12-15 Impact factor: 2.778
Authors: J P Mohr; J L Thompson; R M Lazar; B Levin; R L Sacco; K L Furie; J P Kistler; G W Albers; L C Pettigrew; H P Adams; C M Jackson; P Pullicino Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: Leila B Mostaço-Guidolin; Michael S D Smith; Mark Hewko; Bernie Schattka; Michael G Sowa; Arkady Major; Alex C-T Ko Journal: J Appl Physiol (1985) Date: 2019-01-10
Authors: Aristeidis H Katsanos; Rohini Bhole; Alexandra Frogoudaki; Sotirios Giannopoulos; Nitin Goyal; Agathi-Rosa Vrettou; Ignatios Ikonomidis; Ioannis Paraskevaidis; Konstantinos Pappas; John Parissis; Athanassios P Kyritsis; Anne W Alexandrov; Nikos Triantafyllou; Marc D Malkoff; Konstantinos Voumvourakis; Andrei V Alexandrov; Georgios Tsivgoulis Journal: Neurology Date: 2016-08-03 Impact factor: 9.910
Authors: Shinichi Iwata; Zhezhen Jin; Joseph E Schwartz; Shunichi Homma; Mitchell S V Elkind; Tatjana Rundek; Ralph L Sacco; Marco R Di Tullio Journal: Atherosclerosis Date: 2012-01-10 Impact factor: 5.162
Authors: Katie L Ciesienski; Yan Yang; Ilknur Ay; Daniel B Chonde; Galen S Loving; Tyson A Rietz; Ciprian Catana; Peter Caravan Journal: Mol Pharm Date: 2013-01-30 Impact factor: 4.939